...
机译:膜相关的法呢基化的UCH-L1促进α-突触核蛋白的神经毒性,是帕金森氏病的治疗靶标
Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139 Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;
Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139 Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;
Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;
Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;
Laboratory of Neurogenetics, National Institutes of Health, Building 35, 9000 Rockville Pike, Bethesda, MD 20892;
Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139;
Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;
Center for Neurologic Diseases, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139 Link Medicine Corporation, 161 First Street, Cambridge, MA 02142;
机译:miR-486-3p通过靶向SIRT2基因和导致帕金森氏病的靶位点多态性影响α-突触核蛋白的神经毒性
机译:氧化铜纳米粒子促进α-突触核蛋白寡聚化和神经毒性作为帕金森病的模型
机译:帕金森病的靶向蛋白:促进疾病修饰治疗的进展
机译:帕金森病靶蛋白α-突触核蛋白的结构表征与抗体表位鉴定,使用亲和力 - 质谱法
机译:帕金森氏病中α-突触核蛋白神经毒性的机制。
机译:膜相关的法呢基化的UCH-L1促进α-突触核蛋白的神经毒性,是帕金森氏病的治疗靶标
机译:膜相关的法呢基化的UCH-L1促进α-突触核蛋白的神经毒性,是帕金森氏病的治疗靶标